Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11 β
{fullname}
About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts
Related posts
---
Miracell Receives FDA 510(k) Clearance for SMART M-CELL PRP Concentration System and SMART M-CELL Bone Marrow Concentration System
Blood- and bone marrow-based efficient growth factors extraction system demonstrates substantial equivalence
---
UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study
SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech
---
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- The research team led by Dr. Yuejun Chen, founder of UniXell Biotech,
---
Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics
HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company
---
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary studies - Key
---
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in
